Intas Pharmaceuticals
Biosimilar developer, India. 12 development products across 12 molecules: bevacizumab, denosumab, etanercept, filgrastim, follitropin alfa, interferon alfa-2b, pegfilgrastim, pertuzumab, ranibizumab, rituximab, teriparatide, trastuzumab.
First approval in the Atlas: Nov 2010, Intas Biopharmaceuticals (INN only), teriparatide (CDSCO)
FDAproducts approved3
EMAproducts approved5
PMDAproducts approved0
HCproducts approved2
CDSCOproducts approved10
EDEproducts registered2
Portfolio by market
| Molecule | Product | FDA | EMA | PMDA | HC | CDSCO | EDE |
|---|---|---|---|---|---|---|---|
| Bevacizumab | Intas bevacizumab | · | · | · | · | Jun 2016 | · |
| Denosumab | Osvyrti / Jubereq INTP23 | Oct 2025 | May 2025 | · | · | Jan 2018 | Sep 2025 |
| Etanercept | Intas etanercept | · | · | · | · | Sep 2014 | · |
| Filgrastim | Accofil / Filkri | Jan 2026 | Sep 2014 | · | Dec 2015 | · | · |
| Follitropin alfa | Intas follitropin alfa | · | · | · | · | May 2013 | · |
| Interferon alfa-2b | Intas peginterferon alfa-2b | · | · | · | · | Apr 2013 | · |
| Pegfilgrastim | Pelgraz / Ennumo | May 2026 | Sep 2018 | · | Apr 2018 | · | Dec 2021 |
| Pertuzumab | Intas pertuzumab | · | · | · | · | Jan 2025 | · |
| Ranibizumab | Rexatilux / Razumab | · | Jun 2026 | · | · | Feb 2015 | · |
| Rituximab | Intas rituximab | · | · | · | · | Feb 2013 | · |
| Teriparatide | Sondelbay / Intas teriparatide | · | Mar 2022 | · | · | Nov 2010 | · |
| Trastuzumab | Intas trastuzumab | · | · | · | · | Apr 2018 | · |
Month shown is the first approval or registration of that product in that market.
Chronology
- CDSCONov 2010Intas Biopharmaceuticals (INN only), teriparatide
- CDSCOFeb 2013Intas Pharmaceuticals (INN only), rituximab
- CDSCOApr 2013Intas Biopharmaceuticals (INN only), interferon alfa-2b
- CDSCOMay 2013Intas Biopharmaceuticals (INN only), follitropin alfa
- EMASep 2014Accofil, filgrastim
- CDSCOSep 2014Intas Pharmaceuticals (INN only), etanercept
- CDSCOFeb 2015Razumab, ranibizumab
- HCDec 2015Grastofil, filgrastim
- CDSCOJun 2016Intas Pharmaceuticals (INN only), bevacizumab
- CDSCOJan 2018Intas Pharmaceuticals (INN only), denosumab
- HCApr 2018Lapelga, pegfilgrastim
- CDSCOApr 2018Intas Pharmaceuticals (INN only), trastuzumab
- EMASep 2018Pelgraz, pegfilgrastim
- CDSCOAug 2021Intas Pharmaceuticals (INN only), denosumab
- EDEDec 2021Pelgraz, pegfilgrastim
- EMAMar 2022Sondelbay, teriparatide
- CDSCOJan 2025Intas Pharmaceuticals (INN only), pertuzumab
- EMAMay 2025Jubereq, denosumab
- EMAMay 2025Osvyrti, denosumab
- EDESep 2025Jubereq, denosumab
- EDESep 2025Osvyrti, denosumab
- FDAOct 2025Jubereq, denosumab
- FDAOct 2025Osvyrti, denosumab
- EMANov 2025Vysribli, denosumab
- FDAJan 2026Filkri, filgrastim
- FDAMay 2026Ennumo, pegfilgrastim
- EMAJun 2026Rexatilux, ranibizumab
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.